A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction

MLA

Rao, Sunil V., et al. “A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction.” Circulation (Ovid), vol. 146, no. 16, Oct. 2022, pp. 1196–206. EBSCOhost, https://doi.org/10.1161/CIRCULATIONAHA.122.061612.

APA

Rao, S. V., Kirsch, B., Bhatt, D. L., Budaj, A., Coppolecchia, R., Eikelboom, J., James, S. K., Jones, W. S., Merkely, B., Keller, L., Hermanides, R. S., Campo, G., Ferreiro, J. L., Shibasaki, T., Mundl, H., Alexander, J. H., Hengstenberg, C., Steinwender, C., Alber, H., … Samuelson, B. (2022). A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction. Circulation (Ovid), 146(16), 1196–1206. https://doi.org/10.1161/CIRCULATIONAHA.122.061612

Chicago

Rao, Sunil V., Bodo Kirsch, Deepak L. Bhatt, Andrzej Budaj, Rosa Coppolecchia, John Eikelboom, Stefan K. James, et al. 2022. “A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction.” Circulation (Ovid) 146 (16): 1196–1206. doi:10.1161/CIRCULATIONAHA.122.061612.